Failure modes and effects analysis of pediatric I‐131 MIBG therapy: program design and potential pitfalls
NM Maughan, JL Garcia‐Ramirez… - Pediatric Blood & …, 2022 - Wiley Online Library
Background There is growing interest among pediatric institutions for implementing iodine‐
131 (I‐131) meta‐iodobenzylguanidine (MIBG) therapy for treating children with high‐risk …
131 (I‐131) meta‐iodobenzylguanidine (MIBG) therapy for treating children with high‐risk …
Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium‐177 prostate‐specific membrane antigen …
JE Zoberi, J Garcia‐Ramirez… - Journal of applied …, 2023 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a cell surface protein highly expressed in
nearly all prostate cancers, with restricted expression in some normal tissues. The …
nearly all prostate cancers, with restricted expression in some normal tissues. The …
Radiation safety aspects of iodine-131 metaiodobenzylguanidine (131I mIBG) therapy program startup
JA Barnes, M de la Guardia, T Easley, H Downs… - Health …, 2018 - journals.lww.com
As a medical center without a pre-existing radiopharmaceutical therapy program, it was a
daunting endeavor to implement a 131 I metaiodobenzylguanidine (mIBG) high-dose …
daunting endeavor to implement a 131 I metaiodobenzylguanidine (mIBG) high-dose …
177Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods
C Donzé, L Rubira, L Santoro, M Viarasakd… - European Journal of …, 2022 - ejhp.bmj.com
Objectives 177 Lu-oxodotreotide (Lutathera) is an intravenous peptide receptor radionuclide
therapy to treat unresectable metastatic digestive neuroendocrine tumours. The …
therapy to treat unresectable metastatic digestive neuroendocrine tumours. The …